Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

By sjmartinez • February 23, 2025

Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Feb 21;194:98-104. doi: 10.1016/j.ygyno.2025.02.013. Epub ahead of print. PMID: 39985870.

Tags: Endometrial cancer, Hematology/Oncology, Platinum-free interval, Publications

Paraneoplastic Trichomegaly as a Harbinger of Metastatic Renal Cell Carcinoma: A Case Report

Reichl A, Callahan R. Paraneoplastic Trichomegaly as a Harbinger of Metastatic Renal Cell Carcinoma: A Case Report. Cureus. 2025 May 6;17(5):e83550. doi: 10.7759/cureus.83550. PMID: 40476135;[...]

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li[...]

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, Le X, Cho BC, Yoneshima Y, Ambrose H, Cavazzina R, Tang KH,[...]